Li L, Wan C, Wen F Q
Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, and Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, and Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, China
Genet Mol Res. 2014 May 16;13(2):3772-86. doi: 10.4238/2014.May.16.1.
X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and response rate of platinum chemotherapy in advanced NSCLC patients. Searches were performed on MEDLINE, PubMed, EMBASE, Chinese Biological Medicine Database, China National Knowledge Infrastructure, and Wangfang Data, covering all relevant studies published up to August 1, 2012. Statistical analyses were performed using the Revman 5.0 and STATA 10.0 software. Two polymorphisms, Arg399Gln (G>A) and Arg194Trp (C>T), were investigated in 19 studies, involving 2152 advanced NSCLC patients. For XRCC1 Arg399Gln, patients carrying two G alleles had a significantly increased response rate of platinum chemotherapy, when compared with those carrying the A allele [odds ratio (OR) = 2.05, 95% confidence interval CI = 1.62-2.60 for GG vs GA+AA]. Similarly, the AA carriers had a 54% decreased response rate compared with the G allele carriers (OR = 0.46, 95%CI = 0.30-0.70 for AA vs GA+GG). For XRCC1 Arg194Trp, patients carrying two C alleles had a 62% decreased response rate compared with those carrying either one or two variant T alleles (OR = 0.38, 95%CI = 0.30-0.48 for CC vs CT+TT). However, although TT carriers had a better response rate compared with the C allele carriers, the difference was not significant (OR = 1.27, 95%CI = 0.92-1.77 for TT vs CC+CT). Based on this meta-analysis, we conclude that XRCC1 polymorphisms are associated with treatment response to platinum chemotherapy in advanced NSCLC patients.
X射线修复交叉互补基因1（XRCC1）多态性与铂类化疗治疗非小细胞肺癌（NSCLC）疗效的个体差异有关；然而，不同研究的结果并不一致。我们进行了一项荟萃分析，以研究XRCC1基因多态性与晚期NSCLC患者铂类化疗反应率之间的关联。检索了MEDLINE、PubMed、EMBASE、中国生物医学数据库、中国知网和万方数据，涵盖截至2012年8月1日发表的所有相关研究。使用Revman 5.0和STATA 10.0软件进行统计分析。在19项研究中对两种多态性，即Arg399Gln（G>A）和Arg194Trp（C>T）进行了研究，涉及2152例晚期NSCLC患者。对于XRCC1 Arg399Gln，与携带A等位基因的患者相比，携带两个G等位基因的患者铂类化疗反应率显著增加[GG与GA+AA相比，优势比（OR）=2.05，95%置信区间（CI）=1.62-2.60]。同样，与G等位基因携带者相比，AA携带者的反应率降低了54%（AA与GA+GG相比，OR = 0.46，95%CI = 0.30-0.70）。对于XRCC1 Arg194Trp，与携带一个或两个变异T等位基因的患者相比，携带两个C等位基因的患者反应率降低了62%（CC与CT+TT相比，OR = 0.38，95%CI = 0.30-0.48）。然而，尽管与C等位基因携带者相比，TT携带者的反应率更好，但差异不显著（TT与CC+CT相比，OR = 1.27，95%CI = 0.92-1.77）。基于这项荟萃分析，我们得出结论，XRCC1多态性与晚期NSCLC患者铂类化疗的治疗反应有关。
